Agios Pharmaceuticals, Inc.
NASDAQ:AGIOBiotechnology
+$0.50 today
- Market cap
- $1.78B
- Beta
- 0.59
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$7.19
Volume 0.60M
Average 1.11M
AGIO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Agios Pharmaceuticals, Inc.NASDAQ: AGIO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows in line with its trailing trend
Q1 FY2026 research & development of $79.79M rose 11.6% year over year, behind the +13.3% change in trailing-twelve-month research & development. Sequentially, it fell 8.1% from the prior quarter. Over 3 fiscal years it compounded at +6.1% a year.
Context
- Research & development amounted to 618.9% of revenue in FY2025, down 206.6 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +11.6% toward the trailing-twelve-month pace of +13.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 334.36M USD
- Year-over-year change
- +11.0%
- 4-year CAGR
- +6.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 334.36M | +11.0% |
| FY2024 | 2024-12-31 | 301.29M | +4.3% |
| FY2023 | 2023-12-31 | 288.9M | +3.2% |
| FY2022 | 2022-12-31 | 279.91M | +8.9% |
| FY2021 | 2021-12-31 | 256.97M | — |
Research & Development vs competitors
How AGIO compares with its peers on the latest reported figures
- AGIO's LTM Mar 2026 research & development of $342.68M is the 3rd highest of the 7 companies compared; the peer median is $240.13M.
- Its year-over-year change of +13.3% is the 5th highest of 7, against a peer median of +18.8%.
- Research & development amounts to 518.8% of revenue for AGIO, versus a peer median of 43.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $770.95M | +12.5% | +2.0% | 115.2% | |
| LTM Jun 2026 | $433.31M | -14.7% | -11.3% | 43.0% | |
| LTM Mar 2026 | $342.68M | +13.3% | +6.1% | 518.8% | |
| LTM Jun 2026 | $282.51M | +68.3% | +20.3% | 45.7% | |
| LTM Jun 2026 | $197.76M | +15.5% | -13.1% | 21.0% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $183.14M | +22.7% | +72.2% | — |
| LTM Mar 2026 | $104.71M | +22.1% | +23.1% | 28.3% | |
| Peer median (excluding AGIO) | $240.13M | +18.8% | +11.2% | 43.0% | |
Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 14.24M | 26.82M | 36.5M | 54.03M |
| Cost of Revenue | 18.78M | 1.7M | 9.5M | 4.17M | 11.52M |
| Gross Profit | (18.78M) | 12.54M | 17.32M | 32.33M | 42.51M |
| Gross Margin | — | 88.0% | 64.6% | 88.6% | 78.7% |
| Research & Development | 256.97M | 279.91M | 288.9M | 301.29M | 334.36M |
| Selling, General & Admin | 121.45M | 121.67M | 119.9M | 156.78M | 180.28M |
| Operating Expenses | 359.64M | 401.58M | 408.81M | 458.07M | 514.64M |
| Depreciation & Amortization | 18.78M | 8.56M | 6.62M | 5.65M | 5.18M |
| EBITDA | (337.73M) | (223.24M) | (345.47M) | 723.62M | (408.62M) |
| EBITDA Margin | — | -1567.7% | -1287.9% | 1982.6% | -756.3% |
| Operating Income | (378.42M) | (389.05M) | (391.49M) | (425.74M) | (472.13M) |
| Operating Margin | — | -2732.1% | -1459.5% | -1166.5% | -873.9% |
| Interest Income | 836K | 12.79M | 33.34M | 48.08M | 56.38M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 21.91M | 157.25M | 39.4M | 1.14B | 58.34M |
| Income Before Tax | (356.51M) | (231.8M) | (352.09M) | 717.97M | (413.8M) |
| Pre-Tax Margin | — | -1627.8% | -1312.6% | 1967.1% | -765.9% |
| Income Tax Expense | 0 | 0 | 0 | 44.24M | (1.02M) |
| Net Income | 1.6B | (231.8M) | (352.09M) | 673.73M | (412.78M) |
| Net Margin | — | -1627.8% | -1312.6% | 1845.9% | -764.0% |
| EPS (Basic) | (6.36) | (4.23) | (6.33) | 11.86 | (7.12) |
| EPS (Diluted) | (6.36) | (4.23) | (6.33) | 11.64 | (7.12) |
| Weighted Avg Shares | 60.45M | 54.79M | 55.65M | 56.81M | 57.97M |
| Weighted Avg Shares (Diluted) | 60.45M | 54.79M | 55.65M | 57.89M | 57.97M |
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.